ALS vs MS vs Guillain-Barre: Board-Relevant Differences for COMLEX and USMLE

The fastest way to separate ALS, MS, and Guillain-Barre on board exams is to ask three questions: is there sensory involvement, what is the time course, and where does the lesion sit. ALS is pure motor with mixed upper and lower motor neuron signs and no sensory loss, usually in a patient over 50. MS is a relapsing-remitting central nervous system disease in a young woman, with sensory symptoms, optic neuritis, and lesions separated in space and time. Guillain-Barre is an acute ascending, symmetric, areflexic paralysis that follows an infection by one to three weeks. Lock those three axes in and these stems stop blending together.

All three show up as differentials in the same weakness vignette because they all cause motor weakness, and the question writers know students collapse them into one answer. The discriminating features are sensory versus pure motor, acute versus chronic, central versus peripheral, and the antibody or CSF finding the stem hands you at the end. This guide walks each disease through the exact features COMLEX and USMLE test, gives you a side-by-side table to drill, and finishes with two board-style practice questions.

Why ALS, MS, and Guillain-Barre get confused on boards

They all present with weakness, and weakness is the single most overloaded chief complaint in neurology. A stem that opens with "progressive weakness" could be heading toward any of the three, plus myasthenia gravis, Lambert-Eaton, and a dozen myopathies. The question is never whether the patient is weak. The real task is figuring out which level of the nervous system is broken and how fast it broke.

Three axes do most of the work:

1. Motor pattern: pure motor (ALS), central with sensory and visual involvement (MS), or peripheral with areflexia (Guillain-Barre)
2. Time course: chronic and relentlessly progressive (ALS), relapsing and remitting over years (MS), or acute over days to a few weeks (Guillain-Barre)
3. Localization signal: mixed UMN and LMN signs together (ALS), lesions disseminated in space and time (MS), or ascending symmetric weakness with a recent infection (Guillain-Barre)

Map a stem onto those three axes and the answer falls out before you reach the confirmatory test. The confirmatory finding (EMG, MRI with oligoclonal bands, or albuminocytologic dissociation) is usually the last sentence, and it should confirm what you already decided, not rescue a guess.

ALS: pure motor, mixed UMN and LMN, no sensory loss

What ALS actually is

Amyotrophic lateral sclerosis is a progressive degeneration of motor neurons at two levels at once. The upper motor neurons in the motor cortex and corticospinal tracts die, and the lower motor neurons in the anterior horn of the spinal cord and the brainstem motor nuclei die. That combination is the whole identity of the disease. You get spasticity, hyperreflexia, and a Babinski sign from the UMN loss, sitting right alongside muscle atrophy, fasciculations, and weakness from the LMN loss, often in the same limb.

Most cases are sporadic. A minority are familial, classically tied to SOD1 gene mutations, and C9orf72 repeat expansions are the most common identified genetic cause and link ALS to frontotemporal dementia. The high-yield mechanism point is that ALS spares sensation, spares eye movements until very late, and usually spares bowel and bladder control. Cognition is typically preserved, though a subset develops frontotemporal dementia.

Board demographics and triggers for ALS

The classic stem is an adult between 50 and 70 with progressive, painless weakness. Two onset patterns get tested:

• Limb onset: asymmetric weakness and atrophy starting in a hand or foot, with the patient noticing dropping objects or tripping, plus visible fasciculations and cramps.
• Bulbar onset: dysarthria, dysphagia, and tongue fasciculations and atrophy, often in an older patient, carrying a worse prognosis. Watch for tongue fasciculations described in the stem because that detail is almost a giveaway.

Board findings and workup for ALS

The single most tested concept is the coexistence of UMN and LMN signs with completely normal sensation. If you want the deeper drill on separating brisk from depressed reflexes and what a Babinski actually localizes, our UMN vs LMN guide breaks it down sign by sign.

Board treatment for ALS

ALS management is mostly supportive, and the disease-modifying options only modestly slow progression. Riluzole, a glutamate-release inhibitor, extends survival by a few months. Edaravone, a free-radical scavenger, slows functional decline in selected patients. Beyond the drugs, the board-relevant points are noninvasive ventilation for respiratory support, nutrition support including gastrostomy for bulbar dysphagia, and multidisciplinary care. There is no cure, and prognosis is typically measured in two to five years from diagnosis, though it varies.

MS: relapsing CNS demyelination in a young woman

What MS actually is

Multiple sclerosis is an autoimmune demyelinating disease of the central nervous system. T cells and antibodies attack the myelin made by oligodendrocytes in the brain, spinal cord, and optic nerves. The hallmark that defines the diagnosis is dissemination in space and time: lesions in different parts of the CNS, appearing at different points in time. That is why a single isolated attack is not enough to call MS outright.

Because the demyelination is central, MS produces upper motor neuron signs, sensory symptoms, visual loss, and coordination problems, in almost any combination. The peripheral nervous system is spared, which is exactly why MS sits on the opposite side of the table from Guillain-Barre.

Board demographics and triggers for MS

The prototypical stem is a woman between 20 and 40, more common at higher latitudes and tied to low vitamin D and prior Epstein-Barr virus exposure. The symptoms classically come and go. High-yield presentations include:

• Optic neuritis: painful monocular vision loss with an afferent pupillary defect, frequently the first attack
• Internuclear ophthalmoplegia: a lesion of the medial longitudinal fasciculus causing impaired adduction on lateral gaze with nystagmus in the abducting eye, and bilateral INO in a young patient is MS until proven otherwise
• Sensory symptoms: numbness, tingling, and the Lhermitte sign, an electric shock down the spine on neck flexion
• Uhthoff phenomenon: symptoms worsening with heat, such as a hot shower or exercise
• Bladder dysfunction, spasticity, and scanning speech as the disease accumulates lesions

Board findings and workup for MS

MRI of the brain and spinal cord is the workhorse, and oligoclonal bands in the cerebrospinal fluid support the diagnosis when imaging is equivocal. The phrase to circle on any stem is "disseminated in space and time," because that wording maps directly onto the diagnostic criteria.

Board treatment for MS

Treatment splits into two buckets, and boards test both. Acute relapses are treated with high-dose IV corticosteroids to shorten the attack, with plasma exchange reserved for severe steroid-refractory relapses. Long-term, disease-modifying therapies reduce relapse frequency, and the tested names include interferon beta, glatiramer acetate, natalizumab, and the anti-CD20 agents like ocrelizumab. The board contrast worth memorizing is that steroids help the acute MS attack, while in Guillain-Barre steroids do not work at all.

Guillain-Barre: acute ascending areflexic paralysis after an infection

What Guillain-Barre actually is

Guillain-Barre syndrome is an acute immune-mediated polyradiculoneuropathy. The most common form in North America and Europe is acute inflammatory demyelinating polyradiculoneuropathy, where the immune system attacks peripheral nerve myelin through molecular mimicry. An infection primes the immune system, and the resulting antibodies cross-react with components of peripheral nerve. The result is a peripheral, lower motor neuron process: ascending symmetric weakness with loss of reflexes.

This is the acute emergency of the three. The weakness can climb to the diaphragm and cause respiratory failure, so monitoring forced vital capacity and negative inspiratory force is a board-tested management point. Autonomic instability, with arrhythmias and blood pressure swings, can also kill, which is why these patients are watched closely.

Board demographics and triggers for Guillain-Barre

The signature setup is weakness that begins one to three weeks after an infection. The classic antecedent is Campylobacter jejuni gastroenteritis, and other triggers include cytomegalovirus, Epstein-Barr virus, Mycoplasma, Zika virus, and recent vaccination or surgery in some stems. Age range is broad, which is part of why the infection timing matters more than the demographic here.

The Miller Fisher variant is the high-yield subtype: the triad of ophthalmoplegia, ataxia, and areflexia, tied to anti-GQ1b antibodies. The axonal variant AMAN is associated with anti-GM1 antibodies and follows Campylobacter.

Board findings and workup for Guillain-Barre

The CSF buzzword is albuminocytologic dissociation, meaning the protein is high while the white cell count stays normal. If a stem hands you that phrase in a patient with ascending weakness, you are done.

Board treatment for Guillain-Barre

The two effective treatments are intravenous immunoglobulin and plasmapheresis, and they are roughly equivalent, so do not combine them. The most tested negative fact is that corticosteroids do not help in Guillain-Barre, which is the exact opposite of MS. The other management priority is supportive: serial respiratory monitoring, intubation if the vital capacity drops, and telemetry for autonomic instability. Most patients recover substantially over weeks to months.

How do you tell ALS, MS, and Guillain-Barre apart fast?

Run the three-question filter in order, and the differential usually resolves on the first or second question. Ask about sensory involvement first, because a pure motor picture with no sensory loss in an older adult points hard at ALS. If there is sensory involvement, ask about time course: relapsing and remitting over years in a young woman is MS, while acute over days after an infection is Guillain-Barre. Confirm with the localization and the test the stem provides at the end.

Here is the side-by-side table to drill until it is automatic. If you can reproduce this from memory, you can handle nearly any version of this question in under 30 seconds.

A quick note on the steroid line, because boards exploit it. Steroids help the acute MS relapse and do nothing for Guillain-Barre, and they are not the answer for ALS. Mixing those up is one of the most common avoidable errors on this differential.

Five stem clues that crack these questions

These patterns repeat across COMLEX and USMLE items. Internalize them and the reading speeds up.

1. Mixed UMN and LMN signs with normal sensation equals ALS. Atrophy and fasciculations sitting next to hyperreflexia and a Babinski sign, with no sensory loss, in an older adult, is the signature no other disease on this list reproduces.

2. Disseminated in space and time with optic neuritis or INO equals MS. A young woman with vision loss in one eye, an electric shock down the spine on neck flexion, and prior episodes that resolved is the relapsing-remitting fingerprint.

3. Ascending symmetric areflexic weakness after an infection equals Guillain-Barre. Weakness that started in the feet and climbed up, with absent reflexes, one to three weeks after diarrhea or a respiratory illness, points to one answer.

4. Albuminocytologic dissociation is Guillain-Barre. Oligoclonal bands are MS. These two CSF findings are clean separators, so memorize which phrase belongs to which disease and you will never trade them.

5. Steroids: yes for MS, no for Guillain-Barre. When the question asks for the next step in an acute attack, this single contrast resolves the two demyelinating diseases against each other.

Common board pitfalls and how to avoid them

Pitfall 1: Treating Guillain-Barre with steroids. The reflex from MS bleeds over, but steroids are ineffective in Guillain-Barre. The answer is IVIG or plasmapheresis, never both together.

Pitfall 2: Forgetting that ALS spares sensation. If the stem gives you any genuine sensory level or sensory loss, ALS is wrong. ALS is pure motor, and the presence of real sensory findings should push you toward a myelopathy or a peripheral neuropathy instead.

Pitfall 3: Missing respiratory monitoring in Guillain-Barre. The tested next step in a patient with rising weakness is often serial forced vital capacity, not imaging. Patients die from diaphragmatic failure and autonomic instability, so the monitoring answer is frequently correct.

Pitfall 4: Calling MS off a single attack. One episode of optic neuritis is a clinically isolated syndrome, not confirmed MS, until there is dissemination in space and time. Boards reward the student who knows the diagnosis needs more than one event or MRI evidence of older lesions.

Pitfall 5: Overlooking bulbar onset ALS. Tongue fasciculations, dysarthria, and dysphagia in an older patient are easy to misread as a stroke or a cranial nerve problem. The combination with limb UMN and LMN signs is ALS.

Practice questions

These two questions test the differential pattern directly. Cover the answer choices, work through the stem, then check yourself.

Question 1

A 28-year-old woman presents with two days of painful vision loss in her right eye. She reports that 8 months ago she had an episode of numbness and tingling in both legs that resolved over several weeks. On examination, visual acuity is reduced in the right eye with a right afferent pupillary defect. On attempted left lateral gaze, the right eye fails to adduct fully and the left eye shows nystagmus. Lower extremity reflexes are brisk, and there is a bilateral Babinski sign. Which of the following findings is most likely on further evaluation?

A. Albuminocytologic dissociation on lumbar puncture B. Denervation potentials on electromyography across multiple regions C. Oligoclonal bands on cerebrospinal fluid analysis D. Severely reduced ADAMTS13 activity E. Anti-acetylcholine receptor antibodies

Correct answer: C

This patient has multiple sclerosis. The presentation combines optic neuritis (painful monocular vision loss with an afferent pupillary defect) and an internuclear ophthalmoplegia (impaired adduction on lateral gaze with nystagmus in the abducting eye), plus upper motor neuron signs, and a prior self-resolving sensory episode. That history demonstrates central demyelination disseminated in space and time. Cerebrospinal fluid analysis classically shows oligoclonal bands and an elevated IgG index (C is correct). Albuminocytologic dissociation is the cerebrospinal fluid finding in Guillain-Barre syndrome, a peripheral process with areflexia, not brisk reflexes (A is wrong). Denervation on EMG is the ALS pattern, which is pure motor with no sensory or visual involvement (B is wrong). Reduced ADAMTS13 activity defines thrombotic thrombocytopenic purpura, unrelated here (D is wrong). Anti-acetylcholine receptor antibodies indicate myasthenia gravis, which causes fatigable weakness without upper motor neuron signs or a true afferent pupillary defect (E is wrong).

Question 2

A 54-year-old man presents with 9 months of progressive weakness. He first noticed difficulty buttoning his shirt with his right hand, and he now reports frequent muscle cramps and twitching in both arms. On examination there is atrophy and fasciculations of the intrinsic hand muscles bilaterally, with spasticity and hyperreflexia in the lower extremities and bilateral extensor plantar responses. Sensory examination is normal throughout. Bowel and bladder function are intact. Which of the following is the most likely diagnosis?

A. Guillain-Barre syndrome B. Multiple sclerosis C. Amyotrophic lateral sclerosis D. Myasthenia gravis E. Cervical spondylotic myelopathy

Correct answer: C

This is amyotrophic lateral sclerosis. The defining feature is the coexistence of lower motor neuron signs (atrophy, fasciculations, cramps) and upper motor neuron signs (spasticity, hyperreflexia, extensor plantar responses) in a patient over 50, with completely normal sensation and preserved bowel and bladder function (C is correct). Guillain-Barre is acute, ascending, areflexic, and follows an infection, none of which fits a 9-month progressive course (A is wrong). Multiple sclerosis is a central process with sensory and visual involvement, and it would not produce diffuse fasciculations and atrophy (B is wrong). Myasthenia gravis causes fatigable weakness, often ocular and bulbar, without atrophy, fasciculations, or upper motor neuron signs (D is wrong). Cervical spondylotic myelopathy can mimic ALS with mixed signs, but it typically produces a sensory level and often bladder symptoms, and the normal sensation plus widespread fasciculations make ALS the better answer (E is wrong).

Frequently asked questions about ALS, MS, and Guillain-Barre

What is the single fastest way to tell these three apart on boards?

Start with sensory involvement and time course. ALS is pure motor with no sensory loss and a chronic, progressive course in an older adult, and it uniquely shows mixed upper and lower motor neuron signs together. MS has sensory and visual symptoms with a relapsing-remitting course in a young woman, disseminated in space and time. Guillain-Barre is acute, ascending, symmetric, and areflexic, beginning one to three weeks after an infection. Two questions, sensory yes or no and acute or chronic, resolve most stems before you reach the confirmatory test.

Which one is the medical emergency?

Guillain-Barre is the acute emergency of the three. The ascending weakness can reach the diaphragm and cause respiratory failure, so serial monitoring of forced vital capacity and negative inspiratory force is essential, with intubation if respiratory function declines. Autonomic instability can also cause dangerous arrhythmias and blood pressure swings. That is why the tested next step in a Guillain-Barre stem is often respiratory monitoring rather than imaging, and why these patients are managed in a monitored setting.

Why do steroids work for MS but not for Guillain-Barre?

This is a high-yield contrast. Acute MS relapses are treated with high-dose IV corticosteroids to shorten the attack, and plasma exchange is reserved for severe steroid-refractory relapses. Guillain-Barre, despite also being immune-mediated, does not respond to corticosteroids, and the effective treatments are intravenous immunoglobulin or plasmapheresis (not both together). Boards exploit the assumption that any autoimmune neurologic disease responds to steroids, so memorize that steroids help the acute MS attack and do nothing in Guillain-Barre.

What CSF findings distinguish these diseases?

The cerebrospinal fluid gives two clean separators. Guillain-Barre shows albuminocytologic dissociation, meaning elevated protein with a normal white cell count. MS shows oligoclonal bands and an elevated IgG index, supporting central demyelination. ALS has a largely normal CSF, and its diagnostic workhorse is electromyography showing denervation across multiple regions, with MRI used mainly to exclude mimics. If a stem hands you a CSF result, match the phrase to the disease and the answer usually follows immediately.

How do antibody markers help on these questions?

Antibodies mostly help with Guillain-Barre variants. Anti-GQ1b antibodies are associated with the Miller Fisher variant (ophthalmoplegia, ataxia, areflexia), and anti-GM1 antibodies are associated with the axonal AMAN variant that follows Campylobacter jejuni. MS does not have a single defining serum antibody, and the supportive CSF finding is oligoclonal bands. ALS has no specific antibody, though familial cases are linked to SOD1 and C9orf72, with C9orf72 also connecting ALS to frontotemporal dementia.

How heavily is this differential tested on COMLEX versus USMLE?

Both exams test it heavily because it integrates neuroanatomy, localization, and management in one item. COMLEX tends to favor the classic vignette pattern, such as ascending weakness after Campylobacter for Guillain-Barre, optic neuritis with internuclear ophthalmoplegia for MS, and mixed UMN and LMN signs with normal sensation for ALS. USMLE Step 1 leans into mechanism, including molecular mimicry in Guillain-Barre, the medial longitudinal fasciculus in MS, and motor neuron degeneration in ALS. If you can reproduce the comparison table from memory, you will handle either exam.

Related guides

• Upper Motor Neuron vs Lower Motor Neuron: a complete guide for COMLEX and USMLE
• ITP vs TTP vs HUS vs DIC: how to differentiate them on board exams
• How to use Anki effectively for COMLEX
• Doctor Lucas DO on YouTube: neurology localization and high-yield clinical comparison videos